It Seems Aileron Therapeutics Inc (NASDAQ:ALRN) Will Go Up. Just Reported Less Shorted Shares

June 17, 2018 - By Maria Brooks

The stock of Aileron Therapeutics Inc (NASDAQ:ALRN) registered a decrease of 5.81% in short interest. ALRN’s total short interest was 188,100 shares in June as published by FINRA. Its down 5.81% from 199,700 shares, reported previously. With 54,400 shares average volume, it will take short sellers 4 days to cover their ALRN’s short positions. The short interest to Aileron Therapeutics Inc’s float is 4.39%.

The stock increased 1.52% or $0.08 during the last trading session, reaching $5.35. About 23,090 shares traded. Aileron Therapeutics, Inc. (NASDAQ:ALRN) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States. The company has market cap of $78.85 million. The companyÂ’s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside. It currently has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

More recent Aileron Therapeutics, Inc. (NASDAQ:ALRN) news were published by: which released: “Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference” on May 29, 2018. Also published the news titled: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” on May 25, 2018.‘s news article titled: “Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at …” with publication date: May 22, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: